Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Emyria Ltd ( (AU:EMD) ) has shared an announcement.
Emyria announced promising interim results from its MDMA-assisted therapy program for PTSD, showing sustained reductions in PTSD symptoms and improved quality of life for patients three months post-treatment. This reinforces the potential of MDMA-assisted therapy to deliver durable clinical benefits and address unmet needs in PTSD care, as the program continues to expand with real-world data driving its refinement.
More about Emyria Ltd
Emyria Limited is a company focused on developing and delivering new treatments for mental health and select neurological conditions. It actively engages with private hospitals and payers to expand its programs and improve access to innovative therapies.
YTD Price Performance: 0%
Average Trading Volume: 325,485
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$15.66M
For a thorough assessment of EMD stock, go to TipRanks’ Stock Analysis page.
